Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation.
Luo YH, Liu H, Wampfler JA, Tazelaar HD, Li Y, Peikert T, Liu D, Leventakos K, Chen YM, Yang Y, Chiou SH, Yang P.
Luo YH, et al. Among authors: liu h, liu d.
J Cancer Res Clin Oncol. 2022 Aug;148(8):2099-2114. doi: 10.1007/s00432-021-03766-5. Epub 2021 Aug 26.
J Cancer Res Clin Oncol. 2022.
PMID: 34436667
Free PMC article.